Alzheimers Disease Diagnostics Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The Alzheimer's disease diagnostics market includes neuroimaging, cerebrospinal fluid analysis, blood-based biomarker tests, and cognitive assessment tools used to detect and stage the disease. Valued at approximately $10.17 billion in 2025, the market is projected to grow to roughly $25 to $26 billion by 2034-2035, implying a sustained compound annual growth rate in the range of 12 to 15 percent. This expansion reflects intensifying global demand for earlier and more accurate detection as the prevalence of Alzheimer's disease continues to rise.

• •Market valued at approximately $10.17 billion in 2025
• •Projected to reach $25-26 billion by 2034-2035
• •Covers neuroimaging, CSF analysis, blood biomarkers, and cognitive assessments

Primary growth drivers include the rapidly aging global population, with the number of people affected by dementia expected to rise substantially, creating enormous demand for diagnostic services. Advances in biomarker research, particularly blood-based tests for phosphorylated tau and amyloid-beta proteins, are making earlier detection more accessible and affordable than traditional PET scans or lumbar punctures. Growing recognition of the importance of early diagnosis for disease-modifying therapies, combined with expanding healthcare reimbursement for cognitive screening, is accelerating adoption across both developed and emerging markets.

• •Rising global elderly population increasing demand for dementia screening
• •Advances in blood-based biomarkers enabling earlier, less invasive detection
• •Disease-modifying therapies driving need for biomarker-confirmed diagnosis

The market spans multiple diagnostic modalities, including neuroimaging techniques such as MRI and PET scans, cerebrospinal fluid biomarker analysis, emerging blood-based tests, and cognitive and functional assessment tools. North America currently leads the market due to high healthcare spending, advanced diagnostic infrastructure, and a large aging population, while Europe follows closely. The Asia-Pacific region is emerging as the fastest-growing area, fueled by improving healthcare access, rising disease awareness, and increasing investments in neurological care across China, Japan, and India.

• •Key modalities include neuroimaging, CSF analysis, blood biomarkers, and cognitive assessments
• •North America leads, with Europe as a close second
• •Asia-Pacific is the fastest-growing region driven by healthcare access expansion

What are the recent trends and outlook?

Blood-based biomarker tests are emerging as a transformative trend, with several companies pursuing minimally invasive options that could greatly expand access to Alzheimer's screening beyond specialized memory clinics. Artificial intelligence and machine learning are being integrated into diagnostic imaging and cognitive assessment tools to improve accuracy and enable earlier detection of disease pathology. The anticipated approval and adoption of disease-modifying therapies, which require confirmed biomarker-based diagnosis, are expected to drive substantial growth in diagnostic volumes and position the market to approach $26 billion by 2035.

• •Blood-based biomarker tests expected to democratize access to Alzheimer's screening
• •AI and machine learning being integrated into imaging and cognitive assessment tools
• •Disease-modifying therapies requiring biomarker confirmation expected to drive diagnostic volume growth